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ABSTRACT
Introduction: Fasting in patients with type 2
diabetes mellitus (T2DM) is associated with
high risk of hypoglycemia. The aim of this
study was to compare the effectiveness and
safety of vildagliptin in T2DM patients fasting
during Ramadan in a real-life setting in Egypt.
Methods: In this 16-week prospective and
noninterventional study, data were collected
up to 6 weeks before and after Ramadan fasting.
Patients who had received vildagliptin or
sulfonylurea (SU) either as dual therapy with
metformin or as monotherapy were enrolled
into the study.
Results: Two hundred fifty four patients were
enrolled in the study, out of which 246 [121
(97.6%) treated with vildagliptin and 125
(99.2%) with SU] were included in the safety
analysis set. A significantly lower proportion of
patients experienced C1 hypoglycemic event
(HE) with vildagliptin as compared to those
receiving SUs (1.7% vs. 19.2%, respectively;
p\0.001). No patient in either group reported
a grade 2 HE. At week 16, mean change in
HbA1c from baseline for vildagliptin and SU
were -0.1% and ?0.3%, respectively, with a
between-treatment difference of -0.4%
(p\0.001). Mean change in body weight from
baseline for vildagliptin and SU were -0.8 and
-0.1 kg, with a between-treatment difference of
-0.7 kg (p = 0.011). A higher proportion of
SU-treated patients experienced adverse events
compared to those treated with vildagliptin
(23.2% vs. 5.8%, respectively), the primary
reason being the high incidence of
hypoglycemia in the SU group (n = 24, 19.2%).
Conclusions: Treatment with vildagliptin was
associated with lower incidence of
hypoglycemia compared with SU and showed
good glycemic and weight control in patients
with T2DM fasting during Ramadan in a
real-life setting in Egypt.
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INTRODUCTION
The prevalence of diabetes mellitus has been
increasing in Egypt. In 2014, over 7.5 million
people (aged 20–79 years) were suffering from
diabetes in Egypt and this number is expected
to increase to 13.1 million by the year 2035
[1, 2]. Approximately, over 80 million people in
Egypt are Muslims and the majority of them
choose to fast during Ramadan [3].
Ramadan is the holy month during which
millions of Muslims across the world fast with
complete faith and devotion. During this
month, Muslims abstain from consuming
food, beverages, and oral medications between
sunrise and sunset for approximately 30 days
[4, 5]. Fasting is not meant to create excessive
hardships for an individual; the Koran exempts
some Muslims from fasting, which include
pregnant or lactating women, the sick, and the
elderly [6]. Consequently, both religious and
medical advice suggests that people with
diabetes should not fast since it could
adversely affect their metabolic condition
[4, 7]. A large epidemiological study (EPIDIAR)
conducted in 13 Muslim countries showed that
fasting during Ramadan [8] reported an
increased risk in hypoglycemia and severe
hyperglycemia by 7.5-fold and fivefold,
respectively, in patients with type 2 diabetes
mellitus (T2DM) [4, 8, 9].
Several Muslims are unaware of the possible
complications of fasting, which include
hyperglycemia, hypoglycemia, and increased
risk of dehydration and thrombosis [9, 10].
The American Diabetes Association developed a
consensus statement on the management of
diabetes during Ramadan, which recommended
individualized management plan, close
follow-up, and structured educational
programs to reduce the risk of complications
[4].
Vildagliptin, a potent and selective
dipeptidyl peptidase-4 (DPP-4) inhibitor,
improves glycemic control by increasing a-
and b-cell responsiveness to glucose [11, 12].
Several long-term clinical trials have reported a
decreased risk of hypoglycemia with
vildagliptin [13]. Across different studies in
T2DM patients who fast during Ramadan,
vildagliptin has been shown to be effective,
safe, well tolerated and associated with a low
incidence of hypoglycemia, as well as good
glycemic and weight control [14–20].
VildagliptIn expeRience compared wiTh
sulfonylUreas obsErved during Ramadan
(VIRTUE) was a large, prospective,
observational, real-life study which pooled
data from ten countries across the Middle East
(Lebanon, Egypt, United Arab Emirates, Oman,
Saudi Arabia, and Kuwait) and South Asia
(Pakistan, India, Bangladesh, and Indonesia)
[19]. This study reports the effectiveness and
safety of vildagliptin as compared to
sulfonylurea (SU) in Muslim patients with
T2DM fasting during Ramadan. In view of
limited data available, the present report
would provide us an opportunity to look into
the perspectives of real-life management of
T2DM in fasting patients during Ramadan in
Egypt.
METHODS
Study Design and Patients
This study was a multicenter, prospective,
noninterventional, observational study
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conducted in Egypt which enrolled 254 patients
at the beginning of Ramadan. Details of the
study design have been previously presented
elsewhere [19]. Patients included in the study
were aged C18 years, with T2DM
for C12 months prior to start of Ramadan
fasting; HbA1c B8.5% (measured within
6 weeks prior to study entry); and treated with
vildagliptin or SU either as dual therapy with
metformin or as monotherapy for at least
4 weeks but not more than 3 years prior to
commencement of fasting.
The study consisted of a 16-week
observational period that included a fasting
period of approximately 4 weeks. During this
observational period, data from each patient
were collected from at least two visits: at
baseline (up to 6 weeks prior to the start of
fasting, pre-Ramadan), and at the end of study
(within 6 weeks after the end of fasting,
post-Ramadan). In addition, data were
collected if the patient made an interim visit
during the fasting period.
Study Assessments
Primary assessment included the proportion of
patients experiencing C1 hypoglycemic event
(HE), categorized as grade 1 (mild), defined as
any reported symptoms by the patient and/or
any blood glucose measurement\3.9 mmol/L,
or grade 2 (severe), defined as the need for
third-party assistance. Secondary assessments
included change in HbA1c and body weight
and treatment adherence from screening visit
(baseline) to the end of the observational
period. Safety assessments included
monitoring and treatment of emergent adverse
events (AEs) and serious adverse events (SAEs) as
described by the physician. HEs based on blood
glucose measurements and symptoms were
recorded by patients in a diary. On failure to
do so, HEs were recorded by the physician at the
end of observational period, as recalled by the
patient. Treatment adherence was based on the
total number of fasting days and number of
doses missed, if any, in those days. Any drug
exposure during fasting was also recorded by
patients in a diary during this period.
Statistical Analysis
The primary analysis set comprised all patients
who received one dose of the study drug at the
beginning of Ramadan and had at least one
efficacy assessment after the start of fasting. The
proportion of patients experiencing C1 HE was
analyzed using a two-sided Fisher’s exact test.
HbA1c assessment was also performed on the
primary analysis set and was analyzed using a
two sample t test. Other assessments, such as
change in body weight and reporting of AEs and
SAEs were performed on the safety population,
which consisted of all patients who received at
least one dose of the study drug at the
beginning of Ramadan and had at least one
safety assessment. Change in body weight was
analyzed using a two sample t test. Missing data
were computed using a last observation carried
forward approach that carried the last post
baseline observation forward to the end of the
study. The p value reported in the study was
descriptive in nature. Data analysis was
performed by DATAMAP GmbH, Freiburg,
Germany using SAS Release 9.3 (SAS Institute
Inc., Cary, NC, USA).
Ethical Considerations
Written informed consent to the collection and
useof datawasobtained fromall participants, and
the study was performed in accordance with the
guidelines for good pharmacoepidemiological
practices, national requirements and
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regulations, in linewith the ethical principles laid
down in the Declaration of Helsinki.
RESULTS
Patient Disposition and Baseline
Characteristics
Of the 254 patients enrolled, 250 [121 (97.6%)
treated with vildagliptin, 125 (99.2%) with SU
and four (100%) with other treatment]
completed the study. Of these, 246 patients
[121 (97.6%) treated with vildagliptin and 125
(99.2%) with SU] were included in the safety
analysis set. Remaining four patients were lost
to follow-up in the study; three (2.4%) and one
(0.8%) in the vildagliptin and SU group,
respectively.
The demographic and baseline
characteristics of the patients by treatment
group are presented in Table 1. Overall,
approximately 56% of patients were men,
mean patient age was 49 years, mean body
weight was 89.9 kg, mean body mass index
(BMI) was 30.8 kg/m2, and mean HbA1c at
baseline was 7.5%. A slight between-group
variation was observed in the mean duration
of T2DM (2.5 and 3.6 years in the vildagliptin
and SU groups, respectively).
The median daily dose of antidiabetic drugs
during the study is provided in Table 2. The
majority of the patients were receiving dual
therapy with metformin; 90.9% (n = 110/121)
in the vildagliptin group and 68.8% (n = 86/
125) in the SU group. The mean (SD) duration
of exposure to the study drug during Ramadan
was 30.0 (0.0) and 29.8 (1.7) days in the
vildagliptin and SU groups, respectively.
Patients fasted for a mean (SD) of 29.7 (1.3)
days in the vildagliptin group as compared to
29.3 (2.7) days in the SU group.
Hypoglycemia
During Ramadan, a significantly lower
proportion of patients experienced C1 HE in
the vildagliptin group (n = 2/121, 1.7%) than in
the SU group [n = 24/125, 19.2% (p\0.001);
Table 3]. No patient in either group experienced
a severe (grade 2) HE during Ramadan. None of
the HEs led to discontinuation from the study.
HbA1c and Body Weight Changes
At the study endpoint, an HbA1c reduction of
0.1% was reported in the vildagliptin group
(baseline 7.7%) as compared to a 0.3% increase
in the SU group (baseline 7.7%), with a
between-treatment difference of -0.4%
(p\0.001) in favor of vildagliptin group (Fig. 1).
Furthermore, vildagliptin group showed a
reduction of 0.8 kg in body weight from pre- to
post-Ramadan as compared to a reduction of
0.1 kg in the SU group, with a between-treatment
difference of -0.7 kg (p = 0.011).
Treatment Adherence
Median daily dose of vildagliptin and SU
throughout the study period remained the
same (Table 2). Mean (SD) number of missed
doses was 0.0 (0.2) and 0.3 (1.2) in the
vildagliptin and SU groups, respectively. There
was no medication change from pre-Ramadan
to post-Ramadan in the vildagliptin group. A
few patients required medication changes at
pre-Ramadan [four (3.2%)] and post-Ramadan
[one (0.85%)] in the SU group.
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Safety
Overall incidence of AEs was higher in the SU
group as compared to the vildagliptin group
(23.2% vs. 5.8%, respectively; Table 4). The
primary reason being the high incidence of
hypoglycemia in the SU group (n = 24, 19.2%).
Other AEs reported were diarrhea, pyrexia and
Table 1 Patient demographic and baseline characteristics (safety set)
Variable Vildagliptin n 5 121 Sulfonylurea n5 125 Total N5 246
Age (years) 48.3 (7.5) 49.7 (8.9) 49.0 (8.2)
Age group, n (%)
\65 years 121 (100) 118 (94.4) 239 (97.2)
Men n (%) 73 (60.3) 64 (51.2) 137 (55.7)
Weight (kg) 89.3 (13.5) 90.5 (15.4) 89.9 (14.4)
BMI (kg/m2) 30.5 (4.9) 31.0 (5.2) 30.8 (5.1)
Duration of T2DM (years) 2.5 (1.6) 3.6 (2.9) 3.0 (2.4)
HbA1c (%) 7.5 (0.8) 7.5 (0.8) 7.5 (0.8)
Pre-Ramadan fasting advice, n (%)
Yes 119 (98.3) 125 (100.0) 244 (99.2)
No 2 (1.7) 0 (0) 2 (0.8)
Diabetes medication changed for fasting during Ramadan, n (%)
Yes 0 (0) 4 (3.2) 4 (1.6)
No 121 (100) 121 (96.8) 242 (98.4)
Values are mean (±SD), unless indicated otherwise
BMI body mass index, SD standard deviation, T2DM type 2 diabetes mellitus, n number of patients
Table 2 Daily dose of diabetes medication at the start and end of Ramadan fasting (safety set)
Vildagliptin n5 121 Sulfonylurea n5 125
Pre-Ramadan Post-Ramadan Pre-Ramadan Post-Ramadan
na Median dose (mg) na Median dose (mg) na Median dose (mg) na Median dose (mg)
Metformin 110 1700.0 110 1700.0 86 1000.0 86 1000.0
Vildagliptin 121 100.0 121 100.0
Glibenclamide 10 5.0 10 5.0
Gliclazide 45 60.0 45 60.0
Glimepiride 69 3.0 69 3.0
Glipizide 1 10.0 1 10.0
n number of patients
a Patients with dosage information provided for the medication of interest
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headache. No SAEs or deaths were reported in
either group. No patient in either group
discontinued treatment due to an AE.
DISCUSSION
This prospective, observational study aimed to
compare the incidences of hypoglycemia
between vildagliptin and SU treatment in
Muslim patients with T2DM who fasted during
Ramadan in Egypt, represents a part of the
already published and pooled data that
included patients from Middle East and South
Asia [19].
A significantly lower proportion of patients
experienced hypoglycemia with vildagliptin as
compared to SU (1.7% vs. 19.2%, p\0.001).
These findings are similar to those reported in
the larger pooled analysis of the VIRTUE study
[5.4% vs. 19.8% with vildagliptin (n = 669) and
SU (n = 621), respectively] [19]. In the
randomized, controlled trial STudy Evaluating
vildAgliptin compareD to gliclazide in patients
with type 2 diabetes FASTing during Ramadan
(STEADFAST; ClinicalTrials.gov identifier,
NCT01758380), the risk of hypoglycemia was
lower with vildagliptin than gliclazide;
however, the difference was not statistically
significant [20]. The authors attributed the
small difference to the controlled study
conditions, wherein patients received special
attention in terms of good advice, treatment,
and glycemic control, and therefore did not
emulate a real-life setting, as observed in the
VIRTUE study [19]. In addition, another
randomized study reported no statistically
significant difference (p = 0.334) in HEs
between vildagliptin-treated patients and
SU-treated patients during Ramadan which
could be due to the timely follow-up with
patients or change in their dietary habits
during the fasting month [21].








Patients with grade 1 hypoglycemic
event
2 (1.7) 24 (19.2)a 0.07 (0.02, 0.31) \0.001*
Patients with grade 2 hypoglycemic
event
0 0 – –
CI conﬁdence interval, n number of patients
* Fishers exact test
a glimepiride, 12/69 (17.4%); gliclazide, 9/45 (20.0%); glibenclamide, 3/10 (30.0%); and glipizide, 0/1 (0.0%)
Fig. 1 Mean (±SE) change in HbA1c pre- to post-
Ramadan in vildagliptin and sulfonylurea groups (primary
analysis set). *p\0.001. BL baseline, n number of patients,
SE standard error
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The present results also concur with the
findings from larger pooled analysis of the
VIRTUE study as well as several observational
studies conducted in patients fasting during
Ramadan across various parts of the world and
following different types of diet and lifestyle
habits [14–20, 22]. In these studies, vildagliptin
consistently showed a lower incidence of
hypoglycemia compared with SUs (including
glimepiride, gliclazide, glibenclamide, and
glipizide). Vildagliptin also showed better
treatment adherence and improved glycemic
control as compared to SUs when administered
as dual therapy with metformin [14–20, 22].
Vildagliptin improves glycemic control by
causing glucose-dependent insulin secretion
through inhibition of the DPP-4 enzyme,
thereby increasing the sensitivity and
responsiveness of b- and a-cells to glucose
[12, 23]. Vildagliptin exhibiting a low risk of
hypoglycemia is likely due to the fact that both
meal-dependent insulin secretion and
suppression of glucagon secretion are
glucose-dependent [11, 24]. The favorable
outcome observed during fasting is due to the
suppression of inappropriate glucagon secretion
during hyperglycemia as well as the
enhancement of glucose-dependent
insulinotropic polypeptide (GIP)-mediated
effect on glucagon, which results in protection
against hypoglycemia. The levels of both
glucagon-like peptide-1 (GLP-1) and GIP
remain high during the inter-meal and
overnight periods, when hypoglycemia is more
likely to occur [12].
Similar findings have been reported with
another DPP-4 inhibitor, sitagliptin, in
randomized pragmatic studies [25, 26]. Results
from studies with vildagliptin and sitagliptin
suggest that DPP-4 inhibitors are safe and
effective treatment options for T2DM patients
fasting during Ramadan [20, 25].
Vildagliptin was associated with a moderate,
but significant reduction in HbA1c from
baseline as compared to SU, with a
between-group difference of -0.4% (p\0.001).
This finding is consistent with other
vildagliptin studies conducted in fasting
patients with T2DM [14, 19]. Results from this
study showed that vildagliptin conferred small
reductions in body weight in patients with
T2DM who fasted during Ramadan. This
finding is in agreement with previous studies
[14, 18] and could be attributed to the low
Table 4 Overall summary of adverse events (safety set)
Event, n (%) Vildagliptin n5 121 Sulfonylurea n5 125
Any AE 7 (5.8) 29 (23.2)
Any SAE 0 (0.0) 0 (0.0)
Discontinuation due to AEs 0 (0.0) 0 (0.0)
Deaths 0 (0.0) 0 (0.0)
Most common AEs by preferred term (C1.7% in any group)
Diarrhea 3 (2.5) 0 (0.0)
Hypoglycemia 2 (1.7) 24 (19.2)
Pyrexia 2 (1.7) 4 (3.2)
AE adverse event, n number of patients, SAE serious adverse event
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incidence of hypoglycemia which might not
have led to defensive eating.
Overall, both groups showed complete
treatment adherence in this study which is in
agreement with the high treatment adherence
observed in the VIRTUE study’s pooled results,
with a low and similar number of missed doses
(0.7 and 0.8 in the vildagliptin and SU groups,
respectively) [19].
This study had several limitations. First,
being an observational study, there are
inherent limitations and bias that accompany
results of observational study works. Second,
blood glucose measurements were not required
to confirm the hypoglycemic episodes as
assessed by the primary endpoint (C1 HE).
Thus, the lack of a confirmatory glucose
measurement may have overestimated the
incidence of hypoglycemia.
CONCLUSIONS
Treatment with vildagliptin was associated with
lower incidence of hypoglycemia when
compared with SU in patients who fast during
month of Ramadan. Furthermore, vildagliptin
showed good glycemic and weight control and
was well tolerated in patients with T2DM
fasting during Ramadan in a real-life setting in
Egypt.
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